Compare Citius Pharmaceuticals Inc (CTXR) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Exxon Mobil Corporation trades at $159.67 (market cap $657.08B). The key difference: Exxon Mobil Corporation is far larger — about 32837.6× Citius Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays a 2.58% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | XOM | |
|---|---|---|
Market Cap | $20.01M | $657.08B |
Sector | Health | Energy |
52-Week High | $1.82 | $171.52 |
52-Week Low | $0.48 | $106.13 |
Enterprise Value | $16.23M | $688.86B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
ExxonMobil (XOM) trades at $159.79, up 4.48% today, showing strong momentum near its consensus price target of $163.71. The stock maintains a bullish technical outlook with support at $156 and resistance at $162. Recent earnings show mixed results with Q2 2026 missing expectations, but profitability remains solid with a 9.07% net margin and 12.55% ROE. The company benefits from high oil prices and strategic Permian Basin operations, though revenue has declined from $398.7B in 2022 to $323.9B in 2025.
XOM presents a balanced investment case with analyst consensus leaning toward Hold (51.85%). Upside potential exists from oil price strength and operational efficiency, but risks include volatile energy markets and declining revenue trends. The stock's current valuation at 20.57x P/E appears reasonable given stable dividends and strong cash flow generation. Institutional sentiment remains cautiously optimistic with price targets suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
